Skip to content

Study · Other design · 2026

5 results

Semaglutide 25 mg Oral Versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes.

Plotkin M, Ivkovic M, Smith I, Rathor N, Chowdhury R, Hodkinson A, Kushner RF

Diabetes, obesity & metabolism1 Jun 2026Cited by 1 (Europe PMC)

PMID42225300 (opens in a new tab)PMCIDPMC13341388 (opens in a new tab)DOI10.1111/dom.70911 (opens in a new tab)PepBankPUB-42225300
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanOther designEfficacy outcome

    In adults with overweight or obesity, an indirect comparison found a small numerical advantage for s.c. semaglutide 2.4 mg over oral 25 mg in percentage weight change (ETD 1.01 percentage points, 95% CI -1.61 to 3.63, treatment regimen), with no significant difference.

    In plain wordsIn adults with overweight or obesity, injected and oral semaglutide gave similar weight loss in an indirect comparison, with a small, uncertain edge for injection.

    Peptide
    Semaglutide
    Outcome
    No significant changePercentage change in body weight, oral versus s.c. semaglutide
    Study

    n: not reported in source

    Comparator
    Oral semaglutide 25 mg versus s.c. semaglutide 2.4 mg (indirect, versus placebo in each trial)
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    oral 25 mg once daily versus s.c. 2.4 mg once weekly · oral and subcutaneousAs given in this study (human).

    Measurements

    ETD, treatment regimen estimand
    1.01 %-points
    s.c. 2.4 mg versus oral 25 mg
    ETD, efficacy estimand
    0.55 %-points
    s.c. 2.4 mg versus oral 25 mg

    Source sentences

    Summary
    For percentage weight change, s.c. semaglutide showed a small numerical advantage (estimated treatment difference [ETD]: 1.01%-points (95% confidence intervals [CI]: -1.61, 3.63) under treatment regimen; 0.55%-points (95% CI: -2.25, 3.35) under efficacy), but well below the FDA's 5% threshold for clinical relevance.
    2 context sentences
    Summary · context
    A naïve Bucher ITC was conducted using data from two well-matched randomized controlled trials: OASIS 4 (once-daily oral semaglutide 25 mg vs. placebo) and STEP 1 (once-weekly s.c. semaglutide 2.4 mg vs. placebo).
    Summary · context
    Both studies enrolled adults with obesity or overweight with ≥ 1 weight-related complication and implemented similar lifestyle changes alongside semaglutide/placebo.
  2. 02HumanOther designEfficacy outcome

    In adults with overweight or obesity, oral and s.c. semaglutide had comparable efficacy for the proportion reaching the weight loss thresholds in an indirect comparison.

    In plain wordsIn adults with overweight or obesity, a similar share of people reached each weight loss target with oral and injected semaglutide in an indirect comparison.

    Peptide
    Semaglutide
    Outcome
    No significant changeProportion achieving 5%, 10%, 15% and 20% weight loss thresholds
    Study

    n: not reported in source

    Comparator
    Oral semaglutide 25 mg versus s.c. semaglutide 2.4 mg (indirect, versus placebo in each trial)
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    oral 25 mg once daily versus s.c. 2.4 mg once weekly · oral and subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Oral and s.c. semaglutide delivered comparable efficacy across all outcomes assessed.
    3 context sentences
    Summary · context
    The ITC compared percentage change in body weight, the proportion of participants achieving ≥ 5%, ≥ 10%, ≥ 15%, ≥ 20% weight loss, changes in cardiometabolic parameters, and quality of life (IWQoL-Lite-CT PF).
    Summary · context
    A naïve Bucher ITC was conducted using data from two well-matched randomized controlled trials: OASIS 4 (once-daily oral semaglutide 25 mg vs. placebo) and STEP 1 (once-weekly s.c. semaglutide 2.4 mg vs. placebo).
    Summary · context
    Both studies enrolled adults with obesity or overweight with ≥ 1 weight-related complication and implemented similar lifestyle changes alongside semaglutide/placebo.
  3. 03HumanOther designEfficacy outcome

    In adults with overweight or obesity, oral and s.c. semaglutide had comparable efficacy for cardiometabolic parameters in an indirect comparison.

    In plain wordsIn adults with overweight or obesity, heart and metabolic health measures changed by similar amounts with oral and injected semaglutide in an indirect comparison.

    Peptide
    Semaglutide
    Outcome
    No significant changeChanges in cardiometabolic parameters
    Study

    n: not reported in source

    Comparator
    Oral semaglutide 25 mg versus s.c. semaglutide 2.4 mg (indirect, versus placebo in each trial)
    Outcome group
    Cardiometabolic risk factors · Metabolic and weight
    Studied dose
    oral 25 mg once daily versus s.c. 2.4 mg once weekly · oral and subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Oral and s.c. semaglutide delivered comparable efficacy across all outcomes assessed.
    3 context sentences
    Summary · context
    The ITC compared percentage change in body weight, the proportion of participants achieving ≥ 5%, ≥ 10%, ≥ 15%, ≥ 20% weight loss, changes in cardiometabolic parameters, and quality of life (IWQoL-Lite-CT PF).
    Summary · context
    A naïve Bucher ITC was conducted using data from two well-matched randomized controlled trials: OASIS 4 (once-daily oral semaglutide 25 mg vs. placebo) and STEP 1 (once-weekly s.c. semaglutide 2.4 mg vs. placebo).
    Summary · context
    Both studies enrolled adults with obesity or overweight with ≥ 1 weight-related complication and implemented similar lifestyle changes alongside semaglutide/placebo.
  4. 04HumanOther designEfficacy outcome

    In adults with overweight or obesity, oral and s.c. semaglutide had comparable efficacy for quality of life in an indirect comparison.

    In plain wordsIn adults with overweight or obesity, quality of life improved by similar amounts with oral and injected semaglutide in an indirect comparison.

    Peptide
    Semaglutide
    Outcome
    No significant changeQuality of life (IWQoL-Lite-CT physical function)
    Study

    n: not reported in source

    Comparator
    Oral semaglutide 25 mg versus s.c. semaglutide 2.4 mg (indirect, versus placebo in each trial)
    Outcome group
    Exercise and physical function · Metabolic and weight
    Studied dose
    oral 25 mg once daily versus s.c. 2.4 mg once weekly · oral and subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Oral and s.c. semaglutide delivered comparable efficacy across all outcomes assessed.
    3 context sentences
    Summary · context
    The ITC compared percentage change in body weight, the proportion of participants achieving ≥ 5%, ≥ 10%, ≥ 15%, ≥ 20% weight loss, changes in cardiometabolic parameters, and quality of life (IWQoL-Lite-CT PF).
    Summary · context
    A naïve Bucher ITC was conducted using data from two well-matched randomized controlled trials: OASIS 4 (once-daily oral semaglutide 25 mg vs. placebo) and STEP 1 (once-weekly s.c. semaglutide 2.4 mg vs. placebo).
    Summary · context
    Both studies enrolled adults with obesity or overweight with ≥ 1 weight-related complication and implemented similar lifestyle changes alongside semaglutide/placebo.
  5. 05HumanOther designSafety outcome

    In adults with overweight or obesity, safety profiles of oral and s.c. semaglutide were broadly comparable in a descriptive indirect comparison.

    In plain wordsIn adults with overweight or obesity, side effects of oral and injected semaglutide looked broadly similar in an indirect comparison.

    Peptide
    Semaglutide
    Outcome
    No significant changeSafety profile comparison
    Study

    n: not reported in source

    Comparator
    Oral semaglutide 25 mg versus s.c. semaglutide 2.4 mg (indirect, versus placebo in each trial)
    Outcome group
    Adverse events · Whole body
    Studied dose
    oral 25 mg once daily versus s.c. 2.4 mg once weekly · oral and subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Safety profiles were broadly comparable.
    3 context sentences
    Summary · context
    Safety outcomes were descriptively compared.
    Summary · context
    A naïve Bucher ITC was conducted using data from two well-matched randomized controlled trials: OASIS 4 (once-daily oral semaglutide 25 mg vs. placebo) and STEP 1 (once-weekly s.c. semaglutide 2.4 mg vs. placebo).
    Summary · context
    Both studies enrolled adults with obesity or overweight with ≥ 1 weight-related complication and implemented similar lifestyle changes alongside semaglutide/placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.